Diphtheria, Tetanus, and Acellular Pertussis Vaccine (Intramuscular Route)


Free

E-newsletter

Subscribe to Housecall

Our weekly general interest
e-newsletter keeps you up to date on a wide variety of health topics.

Sign up now

Diphtheria, Tetanus, and Acellular Pertussis Vaccine (Intramuscular Route)

Drug Information provided by: Micromedex

US Brand Names

  • Daptacel
  • Infanrix
  • Tripedia

Description

Diphtheria, tetanus, and acellular pertussis vaccine (also known as DTaP) is a combination immunizing agent given by injection to protect against infections caused by diphtheria, tetanus (lockjaw), and pertussis (whooping cough). This vaccine is given only to infants and children 6 weeks through 6 years of age (before the child's 7th birthday).

Diphtheria is a serious illness that can cause breathing difficulties, heart problems, nerve damage, pneumonia, and possibly death. The risk of serious complications and death is greater in very young children and in the elderly.

Tetanus (also known as lockjaw) is a serious illness that causes convulsions (seizures) and severe muscle spasms that can be strong enough to cause bone fractures of the spine. Tetanus causes death in 30 to 40 percent of cases.

Pertussis (also known as whooping cough) is a serious disease that causes severe spells of coughing that can interfere with breathing. Pertussis also can cause pneumonia, long-lasting bronchitis, seizures, brain damage, and death.

Diphtheria, tetanus, and pertussis are serious diseases that can cause life-threatening illnesses. Although some serious side effects can occur after a dose of DTaP (usually from the pertussis vaccine part), this rarely happens. The chance of your child catching one of these diseases, and being permanently injured or dying as a result, is much greater than the chance of your child getting a serious side effect from the DTaP vaccine.

This vaccine is to be administered only by or under the supervision of your child's doctor or other health care professional.

This product is available in the following dosage forms:

  • Suspension
Before Using
DR602551 Portions of this document last updated: Sept. 1, 2012

Source: Drug Information provided by: Micromedex

Copyright © 2013 Thomson Healthcare Inc. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.

Advertisement


Text Size: smaller largerlarger